CHEPLAPHARM AG, a leading international platform for well-established branded medicines, has entered into a definitive agreement on a structured investment with US-based Atlantic Park and Singapore-based GIC, two global investment firms, with a total volume of €550 million. The investment will strengthen and diversify CHEPLAPHARM's funding as it pursues its next phase of growth.

Both investors have a strong track record in long-term value creation and growth investing.

CHEPLAPHARM operates a highly scalable and asset-light business model focused on investing in well-established originator brands from research-based pharmaceutical companies. The company has grown dynamically and profitably in recent years with an average growth rate (CAGR) of 47% over the last decade.

In 2021, CHEPLAPHARM continued its profitable growth trajectory and reached a revenue level above the €1 billion mark for the first time in its history (+69% year-on-year growth to €1,082.0m). EBITDA increased by 86% to €624 million with EBITDA and gross profit margins amounting to 58% and 75%, respectively. Even under the currently challenging macroeconomic conditions, CHEPLAPHARM has shown robust growth in the first half of 2022 with a revenue increase of 20% year-on-year.